NCT00607087 - Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus | Biotech Hunter

Enrollment

289

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions

Diabetes Mellitus, Type 1

Interventions

DRUG

Insulin glulisine

100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump

DRUG

Insulin lispro

100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump

DRUG

Insulin aspart

100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump

Trial Locations (12)

Sanofi-Aventis Administrative Office, Bridgewater

Sanofi-Aventis Administrative Office, Macquarie Park

Sanofi-Aventis Administrative Office, Vienna

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Budapest

Sanofi-Aventis Administrative Office, Netanya

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, PE Gouda

Sanofi-Aventis Administrative Office, Seoul

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Bromma

Sanofi-Aventis Administrative Office, Guildford Surrey